What Lemme Sold You and What It Actually Is

Lemme Inc., headquartered in New York and incorporated in Delaware, built a direct-to-consumer supplement business on the back of one of the biggest pharmaceutical trends in modern history. Here is what that business actually looks like.

• The product is “Lemme GLP-1 Daily,” sold on lemmelive.com. Its active ingredients are extracts of lemon, orange, and saffron. The lemon extract is marketed under a trademarked name: “Eriomin.”
• Lemme’s marketing positioned the supplement as a natural solution to the same weight-loss problem that blockbuster drugs like Ozempic and Wegovy solve. The company called GLP-1 the “un-hunger” hormone and claimed its product “promote[s] your body’s GLP-1 production.”
• Lemme co-founder Simon Huck stated on the company’s Instagram page that the product “promotes fat loss + reduces hunger” and described it as a way to increase GLP-1 “without having to take a synthetic drug.”
• The company cited clinical studies to lend scientific credibility to these hunger and weight-loss claims. Those same studies showed no weight loss benefit, and the lawsuit argues the company never tested the three-ingredient combination as a single supplement at all.
• A one-month supply costs $90. Subscribers buying a six-month supply pay $378. The company instructs buyers to take two capsules per day with food and advises that “best results” require “consistent, daily use for at least 3-6 months.” That is a potential commitment of $180 to $378 based on claims the underlying science does not support.

The Science They Cited Proves Their Own Ads Wrong

To understand the fraud, you need to understand how GLP-1 actually works in the body. The science is not complicated, and Lemme is banking on you not knowing it.

• GLP-1 (glucagon-like peptide-1) is a hormone made in the small intestine and brain that triggers insulin release, slows stomach emptying, and signals satiety. It is real, and it does matter for weight regulation.
• The problem is durability. Naturally occurring GLP-1 has a half-life of just one to two minutes. The body’s enzymes destroy it almost immediately. No clinical data supports the idea that briefly boosting natural GLP-1 produces sustained weight loss effects.
• What makes Ozempic and Wegovy effective is that pharmaceutical scientists chemically modified GLP-1’s amino acid sequence to resist those enzymes. Semaglutide has a half-life of approximately seven days when injected. That is why weekly injections work. A lemon extract cannot replicate this.
• When you eat a meal, your natural GLP-1 levels rise by approximately 400% to 900%, spiking from a resting concentration of 5-10 pmol/L to roughly 50 pmol/L. Then it degrades in minutes. Lemme’s product claims a 17% boost. That is biologically trivial compared to what eating already does to your GLP-1 levels.
• Ozempic at a 1 mg weekly dose produces a semaglutide blood concentration of approximately 30,000 pmol/L. That is 300,000% to 600,000% higher than resting GLP-1. It lasts more than 5,000 times longer in the body than the natural hormone. Lemme offers 17%.
• The two Eriomin studies Lemme cited in its own marketing tracked participants over 12 weeks at multiple dose levels (200 mg, 400 mg, and 800 mg per day). At every dose, body weight, BMI, fat mass, lean mass, fat percentage, and waist-to-hip ratio were unchanged. Caloric intake was also unchanged.
• The combination of lemon, orange, and saffron extracts in Lemme GLP-1 Daily was never tested together in a single clinical study. Each ingredient was studied separately, and even those individual studies showed no weight loss. Combining them without combined testing means Lemme has no clinical basis for any of its claims about the product consumers actually purchased.

What This Costs People That Never Shows Up in a Settlement

Christina Robins saw an interview on Instagram. Two people, confident and well-dressed, told her that a hormone her body already makes could be nudged upward with a supplement, and that doing so would quiet the cravings and make the weight come off. She was not naive. She was a person who wanted something real and found something that looked real. She went to the website. She read the claims. She subscribed.

She took two capsules a day with food, every day, for more than three months. She did what the label said. She waited for results that Lemme’s own supporting science says would never come. She gained five pounds.

The five pounds are almost beside the point. What matters more is the architecture of the decision. The GLP-1 drug market is a place where real inequality lives: Ozempic works, and Ozempic costs hundreds of dollars a month, and many insurance plans won’t cover it. People who are priced out of that market are not failing to try. They are trying within what they can afford. Lemme positioned itself precisely in that gap, between the people who need help and the pharmaceutical industry that gatekeeps effective treatment behind cost barriers. The product was priced high enough to feel credible ($90 a month signals quality) but low enough to reach people who cannot afford the real drug.

Three months of Lemme GLP-1 Daily at the subscription rate costs $189. Six months costs $378. That is $378 spent by someone who may have been making real sacrifices to afford it, budgeting for a supplement because the actual medical treatment was out of reach. The company did not just fail to deliver a result. It collected that money while knowing, because its own cited research proves it, that the mechanism it was selling could not work.

There is also the quieter damage. When someone spends months taking a supplement that doesn’t work, they often blame themselves. They wonder what they did wrong. They wonder if they were not consistent enough, not patient enough. Lemme built that self-doubt into the product design by requiring “consistent, daily use for at least 3–6 months” before expecting “best results.” That language creates a window long enough to exhaust the subscriber’s patience and blame the consumer when the results don’t arrive.

The people filing this class action are in the tens of thousands. Each one of them had a reason for looking for help. Most of those reasons are not in any court document.

Direct From the Complaint and the Science Lemme Cited

Every quote below comes directly from the court filing (Case No. 1:25-cv-01938) or from the peer-reviewed studies Lemme itself used to justify its claims. This is not a matter of interpretation.

“Supplementation with Eriomin (200, 400, and 800 mg/day) and placebo had no effect on body weight, BMI, lean mass, fat mass, fat percentage, and hip waist ratio.”

Ribeiro C.B., Ramos F.M., Manthey J.A., Cesar T.B. “Effectiveness of Eriomin in managing hyperglycemia and reversal of prediabetes condition: A double-blind, randomized, controlled study.” Phytotherapy Res. (June 11, 2019). Cited in Class Action Complaint para. 12.

• This is the 2019 study Lemme relied on to claim its product supports “healthy weight loss.” The researchers who ran the study explicitly state in their own findings that Eriomin had zero effect on body weight, BMI, lean mass, fat mass, fat percentage, and waist-to-hip ratio. Lemme used this study as proof of efficacy while the study itself refutes that claim.
• Three dose levels were tested (200 mg, 400 mg, and 800 mg per day). None produced weight loss. The complaint notes this explicitly: regardless of dose, no weight metric changed.

“Supplementation with Eriomin had no effect on blood pressure (systolic and diastolic), body weight, BMI, lean mass, fat mass, and ratio hip/waist.”

Cesar T.B., Ramos F.M., Ribeiro C.B. “Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial.” J. of Medicinal Food (Nov. 9, 2022). Cited in Class Action Complaint para. 12.

• This is the 2022 follow-up study, also cited by Lemme. Again: no change in body weight, BMI, lean mass, fat mass, or waist-to-hip ratio. The same researchers, using the same ingredient, reached the same conclusion three years later.
• The complaint characterizes these findings as “hardly surprising” given that a 17% GLP-1 boost is trivial compared to the 400-900% rise that eating alone triggers. The researchers found nothing. The science was clear.

“[W]hile one could argue that research has occurred on these 3 active ingredients individually (ignoring the glaring problems with the quality of that work), no data has been made available regarding the combination of these agents in a single product.”

Munoz, Nini, and Nirenberg, Edward. “ABCDEFG… LEMME Unravel Kourtney Kardashian’s Latest Supplement Fad.” techingitapart.substack.com. Cited in Class Action Complaint para. 20.

• The product sold to consumers combines lemon, orange, and saffron extracts. That combination has never been clinically tested as a single supplement. Lemme’s “clinical support” applies only to ingredients studied in isolation, under separate conditions, in trials with samples the complaint describes as “far too small to derive valid statistical conclusions.”
• The FDA’s own regulatory standard under 21 C.F.R. § 330.10(a)(4)(iv) states that combining active ingredients is only considered safe and effective if doing so does not decrease the safety or effectiveness of any individual ingredient. Lemme never tested whether the combination met that standard.

“So, it’s three clinically studied ingredients for weight management: so burning visceral fat, and then there’s appetite control—so curbing sugar and carb cravings—and arguably like the most important is it increases GLP-1 hormone naturally in your body without having to take a synthetic drug. So we know that 70% of people who are taking GLP-1 medications stop after a year because of side effects…”

Simon Huck, Lemme co-founder, in an interview posted to Lemme’s Instagram and Facebook pages with Kourtney Kardashian Barker present. Cited in Class Action Complaint para. 19.

• This is the pitch, delivered by a company co-founder, to social media followers: Lemme burns visceral fat, controls appetite, curbs sugar and carb cravings, and raises GLP-1 without the side effects of prescription drugs. Every weight-related claim in this statement is contradicted by Lemme’s own cited science.
• The reference to “70% of people who are taking GLP-1 medications stop after a year” weaponizes real patient struggles with expensive, side-effect-prone drugs to sell a supplement that does not work. It targets the exact population most financially and medically vulnerable to this kind of false promise.

How This Played Out: The Timeline

The lawsuit traces a sequence that moves from the founding of the company through the science, the marketing, and the harm to individual consumers.

Societal Impact: Who Gets Hurt and How

Public Health

Lemme’s false advertising operates inside a genuine public health crisis. The GLP-1 medication market addresses real, documented metabolic disease. Exploiting it has specific downstream consequences.

• Obesity affects millions of Americans, and effective GLP-1 agonists are a clinically validated intervention. When people are redirected toward a supplement that does nothing, they delay or abandon access to treatments that work. The longer someone spends on a false solution, the longer they go without real help.
• The class complaint estimates class membership in the “tens of thousands, if not more.” At $90 per month, and with Lemme directing buyers toward three-to-six-month subscription commitments, the aggregate sum redirected away from actual healthcare or legitimate food, fitness, or medical costs is substantial.
• Lemme exploited a genuine barrier: 70% of GLP-1 medication users reportedly stop within a year due to cost and side effects. Lemme’s co-founder used this statistic in marketing to create the impression that Lemme was the safer, cheaper solution. People who most need help with weight management and cannot access or tolerate prescription GLP-1 drugs are the exact people targeted by this pitch. Those are disproportionately lower-income and middle-income Americans.
• Supplements exist in a regulatory gap. Because the FDA does not require pre-market approval for supplements the way it does for drugs, companies can make health-adjacent claims and collect revenue before any enforcement action. By the time a class action is filed, millions in consumer money has already moved.
• The framing of “natural vs. synthetic” in Lemme’s ads actively discourages consumers from pursuing medically supervised treatment. When a company tells someone they can get GLP-1 benefits “without having to take a synthetic drug,” it may push people away from a treatment that carries real health benefits for conditions like type 2 diabetes and obesity-related cardiovascular risk.

Economic Inequality

The price point and marketing strategy of Lemme GLP-1 Daily were designed to extract money from people who cannot afford what actually works.

• Ozempic and Wegovy cost hundreds of dollars per month at list price. Many insurers, particularly those serving lower-income enrollees, do not cover GLP-1 drugs for weight loss. Lemme, at $90 a month, sits just below the threshold of what a cost-pressed consumer might consider extravagant, while still being expensive enough to imply medical-grade credibility.
• The subscription model compounds the economic harm. Customers who sign up for the six-month subscription at $378 are committed before they can reasonably assess whether the product works. Lemme’s own guidance that “best results” take “3-6 months” means a subscriber is instructed to wait through the entire subscription before expecting to see results. By then, the money is gone.
• Celebrity co-founder marketing is a documented tool for reaching aspirational consumer demographics: younger adults and middle-income buyers who trust influencer and celebrity endorsements. These demographics are also the ones most likely to be navigating weight management without adequate healthcare coverage or access to doctors who can prescribe GLP-1 medications.
• The minimum recovery per plaintiff under New York GBL § 349 is $50; under GBL § 350 it is $500. Treble damages are available if the court finds willful conduct. The complaint argues Lemme acted “willfully, wantonly, and with reckless disregard for the truth.” If that finding holds, recovery could scale significantly, but only if individual class members can be identified and the class is certified. That is a process that takes years, during which Lemme continues to sell.

The Numbers Behind the Fraud

Who Is Involved and How

What Now: Who to Contact, What to Watch, What to Do

The lawsuit is in federal court. The class has not yet been certified. Here is where accountability could come from, and what you can do right now.

Key Defendants and Roles (per complaint)

• Lemme Inc.: The named defendant. A Delaware corporation headquartered in New York, NY. Sells Lemme GLP-1 Daily on lemmelive.com.
• Simon Huck: Co-founder of Lemme. Made direct weight-loss and fat-burning claims on the company’s Instagram and Facebook pages, with Kourtney Kardashian Barker present during at least one filmed interview.
• Kourtney Kardashian Barker: Co-founder of Lemme. Present in the social media interview in which the weight-management claims were made and product was promoted. Her public profile is central to the brand’s reach and credibility with consumers.
• Plaintiff’s counsel: Warren Terzian LLP, 222 N Pacific Coast Hwy, Ste 2000, Los Angeles, CA 90245. Contact: tom.warren@warrenterzian.com; dan.terzian@warrenterzian.com; (213) 410-2620. If you purchased Lemme GLP-1 Daily, you may be a class member.

Mutual Aid and Grassroots Resistance

• If you bought Lemme GLP-1 Daily: Document your purchase history, the advertisements you saw, and your physical results. Screenshot the ads and the website claims. This evidence matters for the class action. Contact Warren Terzian LLP directly.
• Dispute the charges: If you subscribed and did not cancel, contact your bank or credit card company. The FTC’s rules on negative option subscriptions may entitle you to a chargeback. Document everything before you call.
• Share the science: The Eriomin study findings are public record. When you see this supplement advertised on social media, leave a comment citing the studies. Platform comment sections are one of the few free tools consumers have to push back on influencer-driven supplement fraud before regulators act.
• Support local access to legitimate healthcare: Community health centers operating under the FQHC (Federally Qualified Health Center) model provide sliding-scale primary care and can connect patients with medically supervised weight management programs. Find one at findahealthcenter.hrsa.gov.
• Push back on the supplement industry’s regulatory gap: Contact your federal representatives about closing the DSHEA loophole that allows supplement companies to market health claims without pre-market FDA approval. The FTC and FDA have received bipartisan pressure to tighten supplement advertising rules. Add your voice.